Cargando…
In vitro immuno-nanotoxicological methods that take pre-existing conditions into account
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier B.V. Published by Elsevier B.V.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461782/ http://dx.doi.org/10.1016/S0378-4274(21)00282-4 |
| _version_ | 1784572066442248192 |
|---|---|
| author | Himly, M. Johnson, L. Mills-Goodlet, R. Hasenkopf, I. Hofer, S. Hofstaetter, N. Geppert, M. Duschl, A. |
| author_facet | Himly, M. Johnson, L. Mills-Goodlet, R. Hasenkopf, I. Hofer, S. Hofstaetter, N. Geppert, M. Duschl, A. |
| author_sort | Himly, M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8461782 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Published by Elsevier B.V. Published by Elsevier B.V. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84617822021-09-24 In vitro immuno-nanotoxicological methods that take pre-existing conditions into account Himly, M. Johnson, L. Mills-Goodlet, R. Hasenkopf, I. Hofer, S. Hofstaetter, N. Geppert, M. Duschl, A. Toxicol Lett Article Published by Elsevier B.V. Published by Elsevier B.V. 2021-09 2021-09-24 /pmc/articles/PMC8461782/ http://dx.doi.org/10.1016/S0378-4274(21)00282-4 Text en Copyright © 2021 Published by Elsevier B.V. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Himly, M. Johnson, L. Mills-Goodlet, R. Hasenkopf, I. Hofer, S. Hofstaetter, N. Geppert, M. Duschl, A. In vitro immuno-nanotoxicological methods that take pre-existing conditions into account |
| title | In vitro immuno-nanotoxicological methods that take pre-existing conditions into account |
| title_full | In vitro immuno-nanotoxicological methods that take pre-existing conditions into account |
| title_fullStr | In vitro immuno-nanotoxicological methods that take pre-existing conditions into account |
| title_full_unstemmed | In vitro immuno-nanotoxicological methods that take pre-existing conditions into account |
| title_short | In vitro immuno-nanotoxicological methods that take pre-existing conditions into account |
| title_sort | in vitro immuno-nanotoxicological methods that take pre-existing conditions into account |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461782/ http://dx.doi.org/10.1016/S0378-4274(21)00282-4 |
| work_keys_str_mv | AT himlym invitroimmunonanotoxicologicalmethodsthattakepreexistingconditionsintoaccount AT johnsonl invitroimmunonanotoxicologicalmethodsthattakepreexistingconditionsintoaccount AT millsgoodletr invitroimmunonanotoxicologicalmethodsthattakepreexistingconditionsintoaccount AT hasenkopfi invitroimmunonanotoxicologicalmethodsthattakepreexistingconditionsintoaccount AT hofers invitroimmunonanotoxicologicalmethodsthattakepreexistingconditionsintoaccount AT hofstaettern invitroimmunonanotoxicologicalmethodsthattakepreexistingconditionsintoaccount AT geppertm invitroimmunonanotoxicologicalmethodsthattakepreexistingconditionsintoaccount AT duschla invitroimmunonanotoxicologicalmethodsthattakepreexistingconditionsintoaccount |